- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoints and Innovative Therapies in Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-10-23
DOI
10.3389/fonc.2018.00464
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
- (2018) Paola Queirolo et al. EUROPEAN JOURNAL OF CANCER
- A patent review of IDO1 inhibitors for cancer
- (2018) Jae Eun Cheong et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
- (2018) Luyan Mu et al. Frontiers in Molecular Neuroscience
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients
- (2017) Fatemeh Namavar Jahromi et al. IMMUNOLOGICAL INVESTIGATIONS
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- ATIM-18. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (NCT02313272)
- (2017) Solmaz Sahebjam et al. NEURO-ONCOLOGY
- Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
- (2017) Dieter Henrik Heiland et al. Oncotarget
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
- (2017) Anna C. Filley et al. Oncotarget
- Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
- (2017) Takashi Nomizo et al. Scientific Reports
- MicroRNA in Glioblastoma: An Overview
- (2017) Barbara Banelli et al. International Journal of Genomics
- Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
- (2017) Paola Queirolo et al. Frontiers in Immunology
- Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
- (2017) Guanzhang Li et al. OncoImmunology
- Cancer immunotherapy: Wound-bound checkpoint blockade
- (2017) Morteza Mahmoudi et al. Nature Biomedical Engineering
- Potential roles of DNA methylation in the initiation and establishment of replicative senescence revealed by array-based methylome and transcriptome analyses
- (2017) Mizuho Sakaki et al. PLoS One
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
- (2016) Ricky Chen et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Investigational new drugs for brain cancer
- (2016) Verena Staedtke et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Genetic and Epigenetic Regulation of PD-1 Expression
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
- (2016) Mitsuto Hanihara et al. JOURNAL OF NEUROSURGERY
- ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)
- (2016) David A. Reardon et al. NEURO-ONCOLOGY
- Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies
- (2016) Wenjing Dong et al. PLoS One
- Tremelimumab: research and clinical development
- (2016) Francisco Javier Ibarrondo et al. OncoTargets and Therapy
- PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
- (2016) Heidrun Gevensleben et al. Oncotarget
- PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
- (2016) Diane Goltz et al. OncoImmunology
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- Prospects of immune checkpoint modulators in the treatment of glioblastoma
- (2015) Matthias Preusser et al. Nature Reviews Neurology
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
- (2015) D. A. Reardon et al. Cancer Immunology Research
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
- (2015) Luana Calabrò et al. Lancet Respiratory Medicine
- CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
- (2015) Margaret K. Callahan et al. Frontiers in Oncology
- Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
- (2015) Hayley P. Ellis et al. Frontiers in Oncology
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
- (2014) George C. Prendergast et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Tim-3 on Peripheral CD4+ and CD8+ T Cells Is Involved in the Development of Glioma
- (2014) Song Han et al. DNA AND CELL BIOLOGY
- Immunocompetent murine models for the study of glioblastoma immunotherapy
- (2014) Taemin Oh et al. Journal of Translational Medicine
- Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
- (2013) P. Queirolo et al. CANCER INVESTIGATION
- Efficiently stimulated adult microglia cross-prime naive CD8+T cells injected in the brain
- (2013) Ulrich Jarry et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
- (2012) Brendan Fong et al. PLoS One
- Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
- (2010) Robert M. Prins et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started